Ruggiero Angelo, Lauro Wanda, Miano Chiara, Villani Alessia, Fabbrocini Gabriella, Marasca Claudio
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Case Rep Dermatol. 2023 Feb 14;15(1):35-39. doi: 10.1159/000525347. eCollection 2023 Jan-Dec.
Hidradenitis suppurativa (HS) is an inflammatory skin disease showing a chronic-remitting course. It has been rarely reported that long-term inflammation in HS could lead to serious complications like cutaneous squamous cell carcinoma. Cemiplimab is a fully human antibody immunotherapy that inhibits programmed cell death protein-1, approved for the treatment of locally advanced squamous cell carcinoma, or metastatic squamous cell carcinoma, in patients not eligible for curative surgery or radiotherapy. Herein, we report the case of a 56-year-old patient developing an invasive SCC on longstanding and unresponsive HS lesions successfully treated with cemiplimab.
化脓性汗腺炎（HS）是一种呈慢性缓解病程的炎症性皮肤病。HS长期炎症导致皮肤鳞状细胞癌等严重并发症的情况鲜有报道。西米普利单抗是一种完全人源化抗体免疫疗法，可抑制程序性细胞死亡蛋白1，已被批准用于治疗不符合根治性手术或放疗条件的局部晚期鳞状细胞癌或转移性鳞状细胞癌患者。在此，我们报告一例56岁患者，其长期不愈的HS病灶上发生了侵袭性鳞状细胞癌，经西米普利单抗成功治疗。
